A Phase 2 interventional study of Methylprednisolone (MP) and Methylprednisolone (MP) in Sepsis and Acute Respiratory Distress Syndrome, sponsored by Bin Du. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Bin Du · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.
Among the 286 studies in Sepsis with a site in China, this one is the 53rd largest by planned enrollment of the 121 interventional ones that give a count, is one of 33 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 88 of the 105 other live ones, and was the 257th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 15 · Phase 4 17
First in 2004; this study’s year is marked. 33 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 118 across the 121 interventional studies, 180 across the 164 observational. Of the 87 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 286 have an industry lead sponsor. The 10 most frequent:
Bin Du is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Bin Du has 1 study filed under Sepsis — fewer than ten, so there is no comparison to draw.
26 of the studies in Sepsis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089186Phase 3Qilu Pharmaceutical Co., Ltd.Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | 2026-12 |
| NCT05623722Jing Cai, MDErector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury | 2026-11-30 |
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 286 studies in Sepsis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether methylprednisolone improves outcomes in critically ill patients with a hyperinflammatory phenotype. It will also evaluate the safety of methylprednisolone at different doses.
The main questions it aims to answer are:
Researchers will compare high-dose methylprednisolone (160mg/d), low-dose methylprednisolone (80mg/d), and placebo (normal saline) to evaluate effectiveness and safety.
Participants will:
Background: Acute respiratory distress syndrome (ARDS) and sepsis are common critical illnesses associated with persistently high mortality. The lack of improvement in overall outcomes despite multiple interventions may be attributable to substantial biological heterogeneity. Both ARDS and sepsis can be classified into hyperinflammatory and hypoinflammatory phenotypes based on clinical variables and/or biomarkers. Previous retrospective and target trial emulation studies suggest differential treatment responses, with hyperinflammatory patients potentially benefiting from corticosteroid therapy.
Objective: The primary objective is to evaluate the preliminary efficacy signal of intravenous methylprednisolone, compared with placebo, in critically ill patients with a hyperinflammatory phenotype. The primary endpoint is the proportion of patients achieving a ≥1.4-point reduction in mean Sequential Organ Failure Assessment (SOFA) score from baseline to Day 9. Secondary objectives include evaluation of 30-day mortality, organ support-free days, safety, and tolerability, and to inform endpoint selection and dose optimization for a future phase III trial.
Study Design: This is a multicenter, randomized, double-blind, placebo-controlled phase II trial. Participants will be randomized using a centralized system with stratified permuted block randomization by study site, with varying block sizes to minimize predictability. Eligible participants will be assigned in a 1:1:1 ratio to high-dose methylprednisolone, low-dose methylprednisolone, or placebo.
Participants:
Inclusion Criteria: Participants must meet all of the following criteria:
① Age ≥18 years; ② Onset of ARDS and/or sepsis within 72 hours.
Exclusion Criteria: Participants meeting any of the following will be excluded:
① High-dose vasopressor requirement, defined as a norepinephrine-equivalent dose (NEE) ≥ 0.25 μg/kg/min; ② Systemic corticosteroid exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any immunosuppressive agent within the same period; ③ Solid-organ transplantation or allogeneic stem-cell transplantation; ④ Severe congenital or acquired immunodeficiency, including HIV infection; ⑤ Brain death, expected death within 24 hours, or advanced malignancy or other end-stage disease with a life expectancy of less than 6 months; ⑥ A do-not-resuscitate order or a decision to withdraw or withhold life-sustaining treatment; ⑦ Life-threatening active fungal infection or active tuberculosis; ⑧Known hypersensitivity to corticosteroids; ⑨Pregnancy or lactation; ⑩ Neuromuscular disease that substantially impairs spontaneous breathing; ⑪ Concurrent participation in another interventional clinical trial; ⑫ Any other clinical condition that, in the opinion of the treating physician or investigator, makes participation inappropriate.
Sample Size: This phase II exploratory trial aims to estimate clinically meaningful effect sizes rather than formally test hypotheses. A total of 150 participants (50 per group) will be enrolled. Assuming a 10% dropout rate, approximately 45 evaluable participants per group are expected. In the published ImmunoSep randomised clinical trial, the primary endpoint-a reduction of at least 1.4 points in mean SOFA score from baseline to days 2-9-was achieved by 35.1% of participants receiving precision immunotherapy and 17.9% receiving placebo, corresponding to an absolute difference of 17.2 percentage points (95% CI 6.8 to 27.2).Using these observed proportions as illustrative assumptions, 45 evaluable participants per group would yield an approximate half-width of 17.9 percentage points for the 95% CI of the absolute difference between an active-dose group and placebo. The sample size is therefore intended to provide preliminary estimates of treatment effects and their uncertainty, while supporting the selection of outcomes and sample-size planning for a future phase III trial.
Interventions: Participants will be randomized to: High-dose group: methylprednisolone 80 mg IV every 12 hours; Low-dose group: methylprednisolone 40 mg IV every 12 hours; or Placebo group: normal saline (100 mL) IV every 12 hours. All treatments will be identical in volume, appearance, and administration. At Day 4, inflammatory phenotype will be reassessed; treatment will be discontinued if phenotype transitions to hypoinflammatory. Otherwise, dose will be halved and continued until Day 7 or ICU discharge. All patients will receive standard ICU care according to guidelines.
Blinding: Double-blind design. Drug preparation will be performed by unblinded personnel, while investigators, clinicians, and patients remain blinded.
Outcomes: Primary outcome is proportion of patients achieving a ≥1.4-point reduction in mean SOFA score from baseline to Day 9. Mean SOFA change is calculated as baseline SOFA minus the average SOFA from Days 2-9. For patients who die before Day 9, SOFA is imputed as 24 thereafter; for discharged patients, last observation carried forward (LOCF) is applied. Secondary outcomes include 30-day all-cause mortality, 30-day organ support-free days (OSFD) and Incidence and severity of adverse events. Exploratory outcomes include ICU and hospital length of stay; ventilator-, vasopressor-, and RRT-free days; phenotype transition rates; biomarkers (CRP, PCT, IL-6, etc.); SOFA score trajectory; Vasoactive-Inotropic Score (VIS); incidence of new infections Statistical Analysis: Analyses will follow the intention-to-treat principle. Primary outcome will be reported as proportions with risk differences and 95% confidence intervals. Secondary and exploratory outcomes will be analyzed descriptively. Results will inform effect size estimation and design of a future phase III trial.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Onset of ARDS and/or sepsis within 72 hours.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Drug: Methylprednisolone (MP)
Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Drug: Methylprednisolone (MP)
Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Drug: Placebo
Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.
Proportion of patients with a decrease in mean Sequential Organ Failure Assessment (SOFA) score ≥1.4 points from baseline to Day 9
The outcome is defined as the proportion of patients achieving a decrease of ≥1.4 points in mean SOFA score from baseline to Day 9. The mean change in SOFA score is calculated as the baseline SOFA score (Day 1) minus the average SOFA score from Days 2 through 9.The lowest possible SOFA score is 0, and the highest is 24. The higher the score, the more severe the organ dysfunction.
Time frame: From baseline (Day 1) to Day 9
30-day Organ Support Free Days (OSFD)
Organ Support Free Days (OSFD) is defined as the number of days within 30 days where the patient survives without the need for any organ support, including respiratory support (mechanical ventilation and extracorporeal membrane oxygenation \[ECMO\]), circulatory support (vasopressors, positive inotropic agents, intra-aortic balloon pump \[IABP\], and ECMO), and renal replacement therapy. If the patient dies within 30 days, OSFD is recorded as 0 days.
Time frame: From randomization to 30 days
30-day mortality
30-day mortality is defined as death from any cause within 30 days after randomization.
Time frame: From randomization to 30 days
Incidence and severity of adverse events and serious adverse events during treatment
The outcome includes the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during the treatment period. Adverse events of interest include hyperglycemia (requiring insulin therapy in non-diabetic patients or increased insulin dosage in diabetic patients), gastrointestinal bleeding, muscle weakness, barotrauma (including pneumothorax, pneumomediastinum, subcutaneous emphysema, or imaging-confirmed findings), new-onset infection (hospital-acquired infections as determined by the treating physician), respiratory acidosis, severe acidosis (pH \< 7.10), refractory hypoxemia (PaO₂ \< 55 mmHg), severe hypotension (mean arterial pressure \< 60 mmHg), new-onset arrhythmia (including atrial fibrillation or supraventricular tachycardia), cardiac arrest, and all reported serious adverse events.
Time frame: During the treatment period (from randomization to Day 7 or ICU discharge, whichever occurs first)
Length of ICU stay
Length of ICU stay is defined as the time from randomization to ICU discharge. Patients who remain in the ICU at 30 days after randomization or die during ICU stay will be assigned a value of 30 days.
Time frame: From randomization to 30 days
Length of hospital stay
Length of hospital stay is defined as the time from randomization to hospital discharge. Patients who remain hospitalized at 30 days after randomization or die during hospitalization will be assigned a value of 30 days.
Time frame: From randomization to 30 days
30-day ventilator-free days (VFD)
Ventilator-free days (VFD) are defined as the number of days from successful extubation to 30 days after randomization. Successful extubation is defined as liberation from mechanical ventilation for at least 48 hours without reintubation. Patients who remain ventilated at 30 days or die within 30 days will be assigned 0 ventilator-free days.
Time frame: From randomization to 30 days
30-day vasopressor-free days
Vasopressor-free days are defined as the number of days from the last discontinuation of circulatory support to 30 days after randomization. Circulatory support includes vasopressors, inotropic agents, intra-aortic balloon pump (IABP), and extracorporeal membrane oxygenation (ECMO). Discontinuation is defined as cessation of vasopressors and inotropes for at least 48 hours without reinitiation. Patients who remain on circulatory support at 30 days or die within 30 days will be assigned 0 vasopressor-free days.
Time frame: From randomization to 30 days
30-day renal replacement therapy-free days
Renal replacement therapy (RRT)-free days are defined as the number of days from the last discontinuation of RRT to 30 days after randomization. Discontinuation is defined as cessation of RRT for at least 48 hours without reinitiation. Patients who remain on RRT at 30 days or die within 30 days will be assigned 0 RRT-free days.
Time frame: From randomization to 30 days
Probability of transition from hyperinflammatory to hypoinflammatory phenotype
The probability of transition from hyperinflammatory to hypoinflammatory phenotype is assessed at Days 1,4, 7, 9, and 15 after randomization.
Time frame: At Days 1,4, 7, 9, and 15 after randomization
Biomarker levels after randomization
Levels of inflammatory biomarkers including C-reactive protein (CRP), procalcitonin (PCT), neutrophil-to-lymphocyte ratio (NLR), interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor-alpha (TNF-α), protein C, soluble tumor necrosis factor receptor 1 (sTNFR1), and ferritin.
Time frame: At Days 1,4, 7, 9, and 15 after randomization
Sequential Organ Failure Assessment (SOFA) score
SOFA scores are assessed longitudinally to evaluate organ dysfunction over time. The lowest possible SOFA score is 0, and the highest is 24. The higher the score, the more severe the organ dysfunction.
Time frame: From Day 1 to Day 9 and Day 15 after randomization
Vasoactive-Inotropic Score (VIS)
VIS is calculated as: dopamine (μg/kg/min) + dobutamine (μg/kg/min) + 10 × milrinone (μg/kg/min) + 100 × epinephrine (μg/kg/min) + 100 × norepinephrine (μg/kg/min) + 10000 × vasopressin (U/kg/min). The minimum VIS score is 0, but there is no fixed maximum score. The higher the score, the greater the dose of vasoactive medications.
Time frame: At Days 1,4, 7, 9, and 15 after randomization
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.
Of 43 non-industry phase 2 interventional studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 35. This study's planned 23 months is below that.
Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylprednisolone